Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.62 |
| ▸ | HTR1D | P28221 | 3/20 | 0.62 |
| ▸ | HTR1B | P28222 | 3/20 | 0.62 |
| ▸ | HTR6 | P50406 | 3/20 | 0.62 |
| ▸ | HTR7 | P34969 | 3/20 | 0.62 |
| ▸ | NCF1 | P14598 | 2/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.62 |
| ▸ | HTR3B | O95264 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | HTR5A | P47898 | 1/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27359418 | 0.98 | HTR1A (0.61) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL17144774 | 0.93 | NCF1 (0.56) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL9643856 | 0.90 | HTR1A (0.74) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| Hydrochloric Acid SCHEMBL7203515 | 0.88 | KDM4E (0.75) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL569714 | 0.82 | HTR1A (0.69) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL1876619 | 0.82 | NCF1 (0.69) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL27554828 | 0.81 | HTR1A (0.59) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL6313298 | 0.81 | HTR1A (0.63) | HTR1AHTR1DHTR1BCYP1A2HTR3A | |
| SCHEMBL6218247 | 0.81 | HTR1A (0.62) | HTR1AHTR1DHTR1BHTR6HTR7 | |
| SCHEMBL9275980 | 0.80 | HTR1A (0.57) | HTR1AHTR1DHTR1BHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110281908-A1 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| EP-1575502-B1 | COMPOSITIONS AND METHODS INVOLVING NUCLEAR HORMONE RECEPTOR SITE II | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-7442554-B2 | Compositions and methods involving glucocorticoid receptor site II | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| EP-1603395-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004080170-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
| EP-0886636-A1 | NOVEL PIPERIDINES DERIVED FROM 1-/(PIPERAZIN-1-YL)ARYL(OXY/AMINO)CARBONYL/-4-ARYL-PIPERIDINE AS SELECTIVE 5-HT-1D.BETA. RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997028140-A1 | NOVEL PIPERIDINES DERIVED FROM 1-/(PIPERAZIN-1-YL)ARYL(OXY/AMINO)CARBONYL/-4-ARYL-PIPERIDINE AS SELECTIVE 5-HT1Db RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | CBR3, L3MBTL3, BRS3 | HTR1A 2209/4885HTR1D 970/4885HTR1B 1877/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | HTR1A 171/4885HTR1D 112/4885HTR1B 71/4885 |
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | HTR1A 288/4885HTR1D 1258/4885HTR1B 441/4885 |
| US-20110281908-A1 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AB2P, HSP90AA1 | HTR1A 2785/4885HTR1D 3755/4885HTR1B 2988/4885 |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | HTR1A 171/4885HTR1D 112/4885HTR1B 71/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | HTR1A 2993/4885HTR1D 1734/4885HTR1B 2983/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | HTR1A 171/4885HTR1D 112/4885HTR1B 71/4885 |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AA1, HSP90AB2P | HTR1A 3718/4885HTR1D 4476/4885HTR1B 4241/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | HTR1A 15/4885HTR1D 14/4885HTR1B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.